Related Experiment Video

Updated: Jan 19, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

Molecular determinants of response to high-dose androgen therapy in prostate cancer

Michael D Nyquist1, Alexandra Corella1, Osama Mohamad2

  • 1Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

JCI Insight
|September 11, 2019
PubMed

Insights

High-dose androgen therapy shows promise for prostate cancer (PC), but identifying responders is challenging. This study reveals genetic factors predicting response to androgen therapy, aiding in selecting suitable patients.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • High-dose androgen (HDA) therapy demonstrates efficacy in prostate cancer (PC) treatment.
  • A significant limitation is the absence of reliable criteria to predict patient response to HDA therapy.

Purpose of the Study:

  • To identify genetic factors and signaling pathways influencing PC cell sensitivity to HDA therapy.
  • To develop a predictive tool for HDA therapy response in prostate cancer patients.

Main Methods:

  • Utilized unbiased genetic screens and transcriptional profiling of PC cells.
  • Analyzed cells with varying sensitivity to androgen-mediated growth repression.

Main Results:

  • Identified specific genetic events and signaling networks crucial for HDA therapy response.
  • Discovered factors that dictate sensitivity to both HDA and androgen withdrawal.

Conclusions:

  • Developed a gene signature for early prediction of HDA therapy response.
  • This signature can help identify prostate cancer patients likely to benefit from HDA therapy.
Keywords:
CancerGeneticsOncologyProstate cancerTumor suppressors

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.7K
Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

11.7K

Related Concept Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

The goal of this protocol is to demonstrate the intra-prostatic injection of prostate cancer cells, with subsequent castration. Orthotopic pre-clinical models of androgen-dependent and castration-resistant prostate cancer are critical to study the disease in the context of a clinically relevant tumor microenvironment and an immunocompetent host.
13.7K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

To demonstrate MR cancer molecular imaging with a small peptide targeted MRI contrast agent specific to clotted plasma proteins in tumor stroma in a mouse prostate cancer...
11.7K
Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Presented here is a protocol to study pharmacological responses in prostate epithelial organoids. Organoids closely resemble in vivo biology and recapitulate patient genetics, making them attractive model systems. Prostate organoids can be established from wildtype prostates, genetically engineered mouse models, benign human tissue, and advanced prostate...
11.7K
Isolation of Cancer Stem Cells From Human Prostate Cancer Samples07:16

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples

The isolation of cancer stem cells (CSCs) directly from human tissues is requisite for their biological characterization. This manuscript describes a methodology for the isolation of prostate CSCs from human tissues, while also providing tips on troubleshooting difficult...
14.6K
Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells08:03

Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells

This manuscript details a method used to generate prostate cancer patient derived xenografts (PDXs) from circulating tumor cells (CTCs). The generation of PDX models from CTCs provides an alternative experimental model to study prostate cancer; the most commonly diagnosed tumor and a frequent cause of death from cancer in...
14.6K
Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer08:54

Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer

We show a method for necropsy and dissection of mouse prostate cancer models, focusing on prostate tumor dissection. A step-by-step protocol for generation of mouse prostate tumor organoids is also...
11.3K